Abbott Laboratories
Abbott's AI exposure sits inside devices and diagnostics rather than in a standalone revenue line. Q2 2026 (July 16) sales were $12.59B, up 13.0% reported but only 4.8% comparable, with Nutrition down 3.6%; full-year guidance is 6.5-7.5% comparable growth and adjusted EPS of $5.45-5.60. The $21B Exact Sciences deal closed March 23 and now reports as Cancer Diagnostics, taking diagnostics to a ~$12B annual run-rate. Ultreon 3.0 (FDA clearance and CE Mark, April 28) extends the AI-guided OCT coronary imaging software Abbott has sold since 2021. On August 11 Abbott and Google announced a Lingo integration with Google's AI Health Coach, rolling out later in 2026 with no financial terms, and Libre Duo 10 Day (glucose and ketone sensing) received FDA authorization on August 25.
Scenarios
Exact Sciences, closed March 23, adds $3B+ of annual revenue in a cancer-diagnostics market growing 15%+ a year, and Cancerguard multi-cancer early detection could reach $5-10B peak revenue as screening guidelines expand. Ultreon 3.0 extends AI-guided coronary imaging into 600K+ US PCI procedures a year, and the Lingo–Google integration puts Abbott glucose data inside a mass-market AI health coach.
The $21B Exact Sciences price (about 7x 2026 revenue) needs Cologuard to keep taking share from colonoscopy and Cancerguard to win broad insurance coverage, neither certain — a negative coverage decision could remove $500M+ of anticipated revenue. Ultreon competes with Philips' cardiovascular AI suite and Medtronic's AI Access platform, both backed by deep hospital relationships. Comparable growth of 4.8% in Q2 2026 and a shrinking Nutrition business show a slower base than the headline, and Abbott's biggest growth drivers (Volt PFA, Libre) are devices rather than AI products.
Key Factors to Watch
- ●Ultreon 3.0 FDA clearance + CE Mark (April 28) — next generation of AI-guided OCT software first launched in 2021; 600K+ US PCI procedures/year
- ●Exact Sciences closed March 23, 2026 — Cologuard growing mid-teens, Cancer Diagnostics now reported as its own line
- ●Google partnership (August 11, 2026) — Lingo CGM data feeds Google's AI Health Coach; rollout later in 2026, no financial terms
Score History
| Date | Score | Direction | Note |
|---|---|---|---|
| 2026-09-26 | 7.0 | Positive | W39 rotation — HOLD 7.0, with three factual corrections. GI Genius is Medtronic's product, not Abbott's, and Volt PFA is not an AI product, so the 'three AI-native product lines' claim is removed; Exact Sciences closed March 23; guidance is 6.5-7.5% comparable. The Google-Lingo AI partnership has not rolled out. md 9 flagged for review because the June first-mover rationale rested on Ultreon being a first, while Abbott has sold AI-guided OCT since 2021. |
| 2026-06-07 | 7.0 | Positive | Score 6.8->7.0 (md 8->9). Ultreon 3.0 received simultaneous FDA clearance and CE Mark (April 28) - first AI-powered OCT coronary imaging system dual-cleared in both the US and Europe, addressing 600K+ US PCI procedures per year. Materiality gate cleared by a named dual-jurisdiction regulatory event creating a multi-year first-mover lead. |
| 2026-03-08 | 6.8 | Positive | Score 7.0->6.8 (are 7->6). External research cross-ref: 7M+ Libre users and 1B+ diagnostic tests create strong data assets but revenue is from devices/diagnostics not AI products directly |
| 2026-03-08 | 7.0 | Positive | Initial assessment from batch 3 research |
Healthcare Peers
Last researched: 2026-09-26
This is research and analysis, not financial advice. Scores reflect AI impact potential, not investment recommendations.